The South Korean biopharmaceutical manufacturer said Monday it signed a land purchase agreement with the Incheon Free Economic Zone authority for about 187,427 square meters of industrial site in Songdo International City. The company will pay 248.7 billion won for the plot, located in the advanced industrial cluster of the city's 11th district.
Samsung Biologics plans to build its third campus on the newly acquired land, housing research and production facilities for cell and gene therapies, antibody vaccines, and peptides alongside existing antibody drug capabilities.
The expansion aims to diversify beyond the company's current antibody-focused CDMO business while building foundational capabilities in next-generation modalities including mRNA, antibody-drug conjugates, and organoids.
The third campus will be designed to integrate with existing operations at the company's first and second campuses through linked process, quality, and technical functions. Samsung Biologics expects the integrated approach to enhance production efficiency, reduce customer project lead times, and strengthen global regulatory compliance.
"We have completed our transformation into a pure CDMO company through the spin-off, and now secured next-generation growth engines through entry into new modalities, allowing us to accelerate toward our goal of becoming a global top bio company," said John Rim, CEO of Samsung Biologics.
reporter
Kim Dong-young
davekim0807@ajupress.com
Copyright ⓒ Aju Press All rights reserved.
